Pittsburgh Compound-B and Alzheimer's Disease Biomarkers in CSF, Plasma and Urine: An Exploratory Study

被引:30
|
作者
Gunnarsson, M. Degerman [1 ]
Lindau, M. [1 ,6 ]
Wall, A. [3 ]
Blennow, K. [4 ]
Darreh-Shori, T. [5 ]
Basu, S. [2 ]
Nordberg, A. [5 ]
Larsson, A. [1 ]
Lannfelt, L. [1 ]
Basun, H. [7 ]
Kilander, L. [1 ]
机构
[1] Uppsala Univ, Dept Publ Hlth Geriatr, Uppsala, Sweden
[2] Uppsala Univ, Dept Publ Hlth Oxidat Stress & Inflammat, Uppsala, Sweden
[3] GE Healthcare Uppsala, Imanet PET Ctr, Uppsala, Sweden
[4] Sahlgrens Univ Hosp, Gothenburg, Sweden
[5] Karolinska Univ Hosp Huddinge, Karolinska Inst, Div Alzheimer Neurobiol, Stockholm, Sweden
[6] Stockholm Univ, Dept Psychol, S-10691 Stockholm, Sweden
[7] BioArctic Neurosci, Stockholm, Sweden
关键词
Pittsburgh Compound-B; PET FDG; Alzheimer's disease; follow-up; Biomarkers; CSF; A beta 1-42; A beta x-42 APOE; Cystatin C; AMYLOID-BETA PROTEIN; CEREBROSPINAL-FLUID; COGNITIVE IMPAIRMENT; TAU-PROTEIN; CYSTATIN-C; WORK GROUP; DEMENTIA; BRAIN; DIAGNOSIS; PREDICTION;
D O I
10.1159/000281832
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background: The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PIB) is an in vivo ligand for measuring beta-amyloid (A beta) load. Associations between PET PIB and cerebrospinal fluid (CSF) A beta 1-42 and apolipoprotein E epsilon 4 (APOE epsilon 4) have been observed in several studies, but the relations between PIB uptake and other biomarkers of Alzheimer's disease (AD) are less investigated. Method: PET PIB, PET 18Fluoro-2-deoxy-D-glucose and different AD biomarkers were measured twice in CSF, plasma and urine 12 months apart in 10 patients with a clinical diagnosis of mild to moderate AD. Results: PIB retention was constant over 1 year, inversely related to low CSF A beta 1-42 (p = 0.01) and correlated positively to the numbers of the APOE epsilon 4 allele (0, 1 or 2) (p = 0.02). There was a relation between mean PIB retention and CSF ApoE protein (r = -0.59, p = 0.07), and plasma cystatin C (r = -0.56, p = 0.09). Conclusion: PIB retention is strongly related to CSF A beta 1-42, and to the numbers of the APOE epsilon 4 allele. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:204 / 212
页数:9
相关论文
共 50 条
  • [1] Cortical Binding of Pittsburgh Compound B, an Endophenotype for Genetic Studies of Alzheimer's Disease
    Hinrichs, Anthony L.
    Mintun, Mark A.
    Head, Denise
    Fagan, Anne M.
    Holtzman, David M.
    Morris, John C.
    Goate, Alison M.
    BIOLOGICAL PSYCHIATRY, 2010, 67 (06) : 581 - 583
  • [2] CSF and plasma biomarkers for early Alzheimer's disease and to monitor Aβ modulation
    Blennow, Kaj
    NEUROBIOLOGY OF AGING, 2008, 29 : S2 - S2
  • [3] Longitudinal Changes of CSF Biomarkers in Alzheimer's Disease
    Seppala, Toni T.
    Koivisto, Anne M.
    Hartikainen, Paivi
    Helisalmi, Seppo
    Soininen, Hilkka
    Herukka, Sanna-Kaisa
    JOURNAL OF ALZHEIMERS DISEASE, 2011, 25 (04) : 583 - 594
  • [4] Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease
    Leuzy, Antoine
    Cullen, Nicholas C.
    Mattsson-Carlgren, Niklas
    Hansson, Oskar
    CURRENT OPINION IN NEUROLOGY, 2021, 34 (02) : 266 - 274
  • [5] Correlations between kynurenines in plasma and CSF, and their relation to markers of Alzheimer's disease pathology
    Bakker, Lieke
    Kohler, Sebastian
    Eussen, Simone J. P. M.
    Choe, Kyonghwan
    van den Hove, Daniel L. A.
    Kenis, Gunter
    Rutten, Bart P. F.
    Ulvik, Arve
    Ueland, Per M.
    Verhey, Frans R. J.
    Ramakers, Inez H. G. B.
    BRAIN BEHAVIOR AND IMMUNITY, 2023, 111 : 312 - 319
  • [6] Alzheimer's Disease and the Routine Clinical Use of CSF Biomarkers
    Martorana, Alessandro
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2017, 16 (04) : 407 - 413
  • [7] Associations of Neprilysin Activity in CSF with Biomarkers for Alzheimer's Disease
    Grimmer, Timo
    Goldhardt, Oliver
    Yakushev, Igor
    Ortner, Marion
    Sorg, Christian
    Diehl-Schmid, Janine
    Foerstl, Hans
    Kurz, Alexander
    Perneczky, Robert
    Miners, Scott
    NEURODEGENERATIVE DISEASES, 2019, 19 (01) : 43 - 50
  • [8] Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology
    Schauer, Stephen P.
    Toth, Balazs
    Lee, Julie
    Honigberg, Lee A.
    Ramakrishnan, Vidya
    Jiang, Jenny
    Kollmorgen, Gwendlyn
    Bayfield, Anna
    Wild, Norbert
    Hoffman, Jennifer
    Ceniceros, Ryan
    Dolton, Michael
    Bohorquez, Sandra M. Sanabria
    Hoogenraad, Casper C.
    Wildsmith, Kristin R.
    Teng, Edmond
    Monteiro, Cecilia
    Anania, Veronica
    Yeh, Felix L.
    ALZHEIMERS & DEMENTIA, 2024, : 8855 - 8866
  • [9] Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography
    Wolk, David A.
    Zhang, Zheng
    Boudhar, Sanaa
    Clark, Christopher M.
    Pontecorvo, Michael J.
    Arnold, Steven E.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2012, 83 (09) : 923 - 926
  • [10] Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate
    Edsbagge, Mikael
    Andreasson, Ulf
    Ambarki, Khalid
    Wikkelso, Carsten
    Eklund, Anders
    Blennow, Kaj
    Zetterberg, Henrik
    Tullberg, Mats
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 58 (03) : 821 - 828